Kite Pharma, Inc.

No Longer Reporting

The company has not filed an annual or quarterly report since its Q2 FY2017 10-Q, filed Aug 8, 2017. Its latest SEC filing is a 15-12B from Oct 13, 2017.

The sections below describe the company as of the FY2016 annual report.

What Did They Do?

Develops cancer treatments by changing a patient's immune cells to attack cancer, for people with blood and solid tumors.

How Did They Make Money?

Revenue came from an Amgen research collaboration: an upfront payment spread across the period of research services and funding as work was performed, plus research-cost reimbursements and payments under an agreement with the Leukemia & Lymphoma Society.

FY2016 revenue

Who Were Their Customers?

Amgen funded research under a collaboration, and the Leukemia & Lymphoma Society provided additional funding. For a potential product launch, Kite planned to reach patients through experienced hospitals and lymphoma centers, with commercial and government payors expected to cover treatment.

Did Revenues Turn Into Profits?

No. It lost $267.1M in FY2016.

Operating income, FY2016

−1232% of revenue

▲ +163% (Loss) vs FY2015 (−$104M, −602%)

Net income, FY2016

−1205% of revenue

▲ +163% (Loss) vs FY2015 (−$101.7M, −589%)

Free cash flow, FY2016

−853% of revenue

▲ +315% (Loss) vs FY2015 (−$45.6M, −264%)

How Were They Changing?

Since the FY2016 annual report

Latest quarter: Q2 FY2017, the three months to Jun 30, 2017

Revenue: ▲ +110%; vs $4.8M in Q2 FY2016
Net income: ▲ +71% (Loss); vs −$64.3M in Q2 FY2016

Oct 3, 2017 Gilead completed its acquisition of Kite Kite became Gilead's wholly owned subsidiary, and its Nasdaq trading was suspended.
Aug 28, 2017 Gilead agreed to acquire Kite The announced deal would pay Kite shareholders in cash.

Who Did They Compete With?

Competes with Novartis, Juno Therapeutics, Adaptimmune, Celgene, bluebird bio, Lion Biotechnologies, Mustang Bio, ZIOPHARM Oncology, Takara Bio, Immunocore, and Cellectis

Comments